Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 72, Issue 8

Utility of in-house and commercial PCR assay in diagnosis of Covid-19 associated mucormycosis in an emergency setting in a tertiary care center No Access

An erratum to this paper has been published here.

Abstract

Invasive mucormycosis (IM) is a potentially fatal infection caused by fungi of the order . Histopathology, culture, and radiology are the mainstays of diagnosis, but they are not sufficiently sensitive, resulting in delayed diagnosis and intervention. Recent studies have shown that PCR-based techniques can be a promising way to diagnose IM.

Early diagnosis of fungal infections using molecular diagnostic techniques can improve patient outcomes, especially in invasive mucormycosis.

The aim of this study was to evaluate the utility of our in-house mould-specific real time PCR assay (qPCR) in comparison with the commercially available real time PCR ( PCR), for the early diagnosis of mucormycosis in tissue samples from patients with suspicion of invasive mucormycosis (IM). This in-house assay can detect and distinguish three clinically relevant mould species, e.g. spp., and spp. in a single reaction with only one pair of primers, without the need for sequencing.

We enrolled 313 tissue samples from 193 patients with suspected IM in this prospective study. All cases were classified using EORTC/MSGERC guidelines. All samples were tested using traditional methods, in-house qPCR, and MucorGenius PCR.

Using direct microscopy as a gold standard, the overall sensitivity and specificity of in-house qPCR for detection of IM was 92.46% and 80% respectively, while that of the MucorGenius PCR was 66.67% and 90% respectively. However, co-infection of IM and IA adversely affected the performance of MucorGenius PCR in detection of IM.

The in-house PCR detected spp. in 14 cases and spp in 4 cases which showed clinical and radiological features of fungal sinusitis. The in-house qPCR also performed better in detecting possible cases of IM. This aids early diagnosis and appropriate treatment to improve patient outcomes.

Because the in-house PCR is not only sensitive and specific, but also entirely based on SYBR Green for detection of targets, it is less expensive than probe-based assays and can be used on a regular basis for the diagnosis of IM in resource-constrained settings. It can be used to distinguish between mucormycosis and fungal sinusitis caused by and in high-risk patients, as well as to accurately detect in fungal co-infection cases.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): invasive aspergillosis , invasive fusariosis , invasive mucormycosis , melting curve analysis , MucorGenius®PCR and real-time PCR
Funding
This study was supported by the:
  • All-India Institute of Medical Sciences (Award A-COVID-104)
    • Principle Award Recipient: ImmaculataXess
© 2023 The Authors

Erratum

An erratum has been published for this content:
Erratum: Utility of in-house and commercial PCR assay in diagnosis of Covid-19 associated mucormycosis in an emergency setting in a tertiary care center
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001745
2023-08-25
2025-03-20
Loading full text...

Full text loading...

References

  1. Hoenigl M, Gangneux J-P, Segal E, Alanio A, Chakrabarti A et al. Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: new leadership is about working together. Mycoses 2018; 61:885–894 [View Article] [PubMed]
     [Google Scholar]
  2. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54 Suppl 1:S23–34 [View Article] [PubMed]
     [Google Scholar]
  3. Danion F, Aguilar C, Catherinot E, Alanio A, DeWolf S et al. Mucormycosis: new developments into a persistently devastating infection. Semin Respir Crit Care Med 2015; 36:692–705 [View Article] [PubMed]
     [Google Scholar]
  4. Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North Am 2016; 30:143–163 [View Article] [PubMed]
     [Google Scholar]
  5. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis 2019; 19:e405–e421 [View Article] [PubMed]
     [Google Scholar]
  6. Arastehfar A, Carvalho A, van de Veerdonk FL, Jenks JD, Koehler P et al. COVID-19 associated pulmonary aspergillosis (CAPA)-from immunology to treatment. J Fungi 2020; 6:91 [View Article] [PubMed]
     [Google Scholar]
  7. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021; 15:102146 [View Article] [PubMed]
     [Google Scholar]
  8. Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol 2021; 69:244 [View Article]
     [Google Scholar]
  9. Ravani SA, Agrawal GA, Leuva PA, Modi PH, Amin KD. Rise of the phoenix: Mucormycosis in COVID-19 times. Indian J Ophthalmol 2021; 69:1563 [View Article]
     [Google Scholar]
  10. Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. Indian J Ophthalmol 2021; 69:1002 [View Article]
     [Google Scholar]
  11. Sikka K, Goel G, Sharma N, Thakar A. Initial and ongoing challenges with COVID-19-associated mucormycosis. Indian J Ophthalmol 2021; 69:3391 [View Article]
     [Google Scholar]
  12. Arora U, Priyadarshi M, Katiyar V, Soneja M, Garg P et al. Risk factors for Coronavirus disease-associated mucormycosis. J Infect 2022; 84:383–390 [View Article] [PubMed]
     [Google Scholar]
  13. Spellberg B, Edwards J, Jr Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18:556–569 [View Article]
     [Google Scholar]
  14. Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E et al. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol Open Access 2018; 56:S93–S101 [View Article]
     [Google Scholar]
  15. Lackner M, Caramalho R, Lass-Flörl C. Laboratory diagnosis of mucormycosis: current status and future perspectives. Future Microbiol 2014; 9:683–695 [View Article] [PubMed]
     [Google Scholar]
  16. White PL, Bretagne S, Klingspor L, Melchers WJG, McCulloch E et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010; 48:1231–1240 [View Article] [PubMed]
     [Google Scholar]
  17. Zaman K, Rudramurthy SM, Das A, Panda N, Honnavar P et al. Molecular diagnosis of rhino-orbito-cerebral mucormycosis from fresh tissue samples. J Med Microbiol 2017; 66:1124–1129 [View Article] [PubMed]
     [Google Scholar]
  18. Baldin C, Soliman SSM, Jeon HH, Alkhazraji S, Gebremariam T et al. PCR-based approach targeting mucorales-specific gene family for diagnosis of mucormycosis. J Clin Microbiol 2018; 56:00746–18 [View Article] [PubMed]
     [Google Scholar]
  19. Millon L, Larosa F, Lepiller Q, Legrand F, Rocchi S et al. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients. Clin Infect Dis 2013; 56:e95–101 [View Article] [PubMed]
     [Google Scholar]
  20. Bialek R, Konrad F, Kern J, Aepinus C, Cecenas L et al. PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J Clin Pathol 2005; 58:1180–1184 [View Article] [PubMed]
     [Google Scholar]
  21. Rickerts V, Just-Nübling G, Konrad F, Kern J, Lambrecht E et al. Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. Eur J Clin Microbiol Infect Dis 2006; 25:8–13 [View Article] [PubMed]
     [Google Scholar]
  22. Kasai M, Harrington SM, Francesconi A, Petraitis V, Petraitiene R et al. Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol 2008; 46:3690–3702 [View Article] [PubMed]
     [Google Scholar]
  23. Alanio A, Garcia-Hermoso D, Mercier-Delarue S, Lanternier F, Gits-Muselli M et al. Molecular identification of Mucorales in human tissues: contribution of PCR electrospray-ionization mass spectrometry. Clin Microbiol Infect 2015; 21:594 [View Article] [PubMed]
     [Google Scholar]
  24. Millon L, Caillot D, Berceanu A, Bretagne S, Lanternier F et al. Evaluation of serum mucorales Polymerase Chain Reaction (PCR) for the diagnosis of mucormycoses: the MODIMUCOR prospective trial. Clin Infect Dis 2022; 75:777–785 [View Article] [PubMed]
     [Google Scholar]
  25. Hammond SP, Bialek R, Milner DA, Petschnigg EM, Baden LR et al. Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol 2011; 49:2151–2153 [View Article] [PubMed]
     [Google Scholar]
  26. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood 2011; 118:1216–1224 [View Article]
     [Google Scholar]
  27. Katragkou A, Walsh TJ, Roilides E. Why is mucormycosis more difficult to cure than more common mycoses?. Clin Microbiol Infect 2014; 20 Suppl 6:74–81 [View Article] [PubMed]
     [Google Scholar]
  28. Pilmis B, Alanio A, Lortholary O, Lanternier F. Recent advances in the understanding and management of mucormycosis. F1000Res 2018; 7:F1000 Faculty Rev-1429 [View Article] [PubMed]
     [Google Scholar]
  29. Dadwal SS, Kontoyiannis DP. Recent advances in the molecular diagnosis of mucormycosis. Expert Rev Mol Diagn 2018; 18:845–854 [View Article] [PubMed]
     [Google Scholar]
  30. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis 2020; 71:1367–1376 [View Article] [PubMed]
     [Google Scholar]
  31. Bialek R, Feucht A, Aepinus C, Just-Nübling G, Robertson VJ et al. Evaluation of two nested PCR assays for detection of Histoplasma capsulatum DNA in human tissue. J Clin Microbiol 2002; 40:1644–1647 [View Article] [PubMed]
     [Google Scholar]
  32. Pandey M, Xess I, Singh G, Kumar R, Mahapatra M et al. Conventional PCR as a reliable method for diagnosing invasive mucormycosis in resource-limited settings. J Med Microbiol 2021; 70: [View Article] [PubMed]
     [Google Scholar]
  33. Pandey M, Xess I, Sachdev J, Yadav U, Singh G et al. Development of a sensitive and specific novel qPCR assay for simultaneous detection and differentiation of mucormycosis and aspergillosis by melting curve analysis. Front Fungal Biol 2022; 2: [View Article]
     [Google Scholar]
  34. Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I et al. Multicenter epidemiologic study of coronavirus disease–associated mucormycosis, India. Emerg Infect Dis 2021; 27:2349–2359 [View Article]
     [Google Scholar]
  35. Pandey M, Singh G, Agarwal R, Dabas Y, Jyotsna VP et al. Emerging Rhizopus microsporus infections in India. J Clin Microbiol 2018; 56:e00433-18 [View Article] [PubMed]
     [Google Scholar]
  36. Herrera DA, Dublin AB, Ormsby E, Aminpour S, Howell LP. Imaging findings of rhinocerebral mucormycosis. Skull Base 2008; 18:S [View Article]
     [Google Scholar]
  37. McAdams HP, Rosado de Christenson M, Strollo DC, Patz EF. Pulmonary mucormycosis: radiologic findings in 32 cases. AJR Am J Roentgenol 1997; 168:1541–1548 [View Article] [PubMed]
     [Google Scholar]
  38. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis 2012; 54 Suppl 1:S55–60 [View Article] [PubMed]
     [Google Scholar]
  39. Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A et al. The emergence of COVID-19 associated mucormycosis: analysis of cases from 18 countries. SSRN Journal 2021 [View Article]
     [Google Scholar]
  40. Singh A, Sikka K, Goel G, Kanodia A, Chandran A et al. Covid-19-associated rhino-orbito-cerebral mucormycosis (CAROM) in Delhi: Demographics and risk factors in a single-centre consecutive cohort of 200 inpatients. Natl Med J India 2022; 35:132–137 [View Article] [PubMed]
     [Google Scholar]
  41. Nithyanandam S, Jacob MS, Battu RR, Thomas RK, Correa MA et al. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol 2003; 51:231–236
     [Google Scholar]
  42. Asai K, Suzuki K, Takahashi T, Ito Y, Kazui T et al. Pulmonary resection with chest wall removal and reconstruction for invasive pulmonary mucormycosis during antileukemia chemotherapy. Jpn J Thorac Cardiovasc Surg 2003; 51:163–166 [View Article] [PubMed]
     [Google Scholar]
  43. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD et al. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994; 57:1044–1050 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001745
Loading
Utility of in-house and commercial PCR assay in diagnosis of Covid-19 associated mucormycosis in an emergency setting in a tertiary care center
J. Med. Microbiol. 72, 001745 (2023); https://doi.org/10.1099/jmm.0.001745
/content/journal/jmm/10.1099/jmm.0.001745
/content/journal/jmm/10.1099/jmm.0.001745
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error